| HMGB1 mediates endogenous TLR2 activation and brain tumor regression JF Curtin, N Liu, M Candolfi, W Xiong, H Assi, K Yagiz, MR Edwards, ... PLoS medicine 6 (1), e1000010, 2009 | 396 | 2009 |
| Gene therapy and targeted toxins for glioma M G Castro, M Candolfi, K M Kroeger, G D King, J F Curtin, K Yagiz, ... Current gene therapy 11 (3), 155-180, 2011 | 118 | 2011 |
| B cells are critical to T-cell—mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma M Candolfi, JF Curtin, K Yagiz, H Assi, MK Wibowo, GE Alzadeh, ... Neoplasia 13 (10), 947-IN23, 2011 | 115 | 2011 |
| Drosophila Bcl‐2 proteins participate in stress‐induced apoptosis, but are not required for normal development EA Sevrioukov, J Burr, EW Huang, HH Assi, JP Monserrate, DC Purves, ... Genesis 45 (4), 184-193, 2007 | 88 | 2007 |
| Gene therapy and virotherapy: novel therapeutic approaches for brain tumors KM Kroeger, AKMG Muhammad, GJ Baker, H Assi, MK Wibowo, W Xiong, ... Discovery medicine 10 (53), 293, 2010 | 73 | 2010 |
| Gene therapy for brain tumors: basic developments and clinical implementation H Assi, M Candolfi, G Baker, Y Mineharu, PR Lowenstein, MG Castro Neuroscience letters 527 (2), 71-77, 2012 | 72 | 2012 |
| Inhaled TLR9 agonist renders lung tumors permissive to PD-1 blockade by promoting optimal CD4+ and CD8+ T-cell interplay M Gallotta, H Assi, É Degagné, SK Kannan, RL Coffman, C Guiducci Cancer research 78 (17), 4943-4956, 2018 | 62 | 2018 |
| Adenoviral vector-mediated gene therapy for gliomas: coming of age MG Castro, M Candolfi, TJ Wilson, A Calinescu, C Paran, N Kamran, ... Expert opinion on biological therapy 14 (9), 1241-1257, 2014 | 50 | 2014 |
| Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy HH Assi, C Paran, N VanderVeen, J Savakus, R Doherty, E Petruzzella, ... Journal of Pharmacology and Experimental Therapeutics 349 (3), 458-469, 2014 | 33 | 2014 |
| Rodent glioma models: intracranial stereotactic allografts and xenografts H Assi, M Candolfi, PR Lowenstein, MG Castro Animal Models of Brain Tumors, 229-243, 2013 | 21 | 2013 |
| Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation M Candolfi, K M Kroeger, W Xiong, C Liu, M Puntel, K Yagiz, ... Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2011 | 20 | 2011 |
| Assessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBM H Assi, J Espinosa, S Suprise, M Sofroniew, R Doherty, D Zamler, ... PLoS One 9 (5), e96318, 2014 | 19 | 2014 |
| Conditional PD-1/PD-L1 Probody therapeutics induce comparable antitumor immunity but reduced systemic toxicity compared with traditional anti–PD-1/PD-L1 agents HH Assi, C Wong, KA Tipton, L Mei, K Wong, J Razo, C Chan, B Howng, ... Cancer Immunology Research 9 (12), 1451-1464, 2021 | 15 | 2021 |
| Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H J Lynes, M Wibowo, C Koschmann, GJ Baker, V Saxena, A Muhammad, ... Neurotherapeutics 11 (3), 623-635, 2014 | 12 | 2014 |
| A probody drug conjugate targeting CD166 (ALCAM) enhances preclinical antitumor activity of a probody therapeutic targeting PD-1 EL Scolan, T Tse, M Krimm, W Garner, H Assi, J Razo, L Wong, K Wong, ... Cancer Research 79 (13_Supplement), 3202-3202, 2019 | 5 | 2019 |
| 706 Conditional cytokine therapeutics for tumor-selective biological activity: preclinical characterization of a dual-masked IFN-a2b A Berezhnoy, H Wang, N Cai, H Assi, N Lapuyade, M Paidhungat, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A735-A735, 2021 | 3 | 2021 |
| Effect of caveolin-1 on Stat3-ptyr705 levels in breast and lung carcinoma cells M Geletu, Z Taha, R Arulanandam, R Mohan, HH Assi, MG Castro, ... Biochemistry and Cell Biology 97 (5), 638-646, 2019 | 2 | 2019 |
| Immunotherapies for brain cancer: from preclinical models to human trials TJ Wilson, M Candolfi, H Assi, MM Ayala, Y Mineharu, SL Hervey-Jumper, ... Tumors of the Central Nervous System, Volume 13: Types of Tumors, Diagnosis …, 2014 | 2 | 2014 |
| Tumor infiltrating B cells as antigen presenting cells: their role in mediating the anti-tumoral immune response induced by a combined immune-stimulatory/conditional cytotoxic … M Candolfi, J Curtin, K Yagiz, H Assi, K Kroeger, M Tesarfreund, A Alden, ... CANCER RESEARCH 69, 2009 | 2 | 2009 |
| Activatable cytokine constructs and related compositions and methods S Mitra, NG Lapuyade, HH Assi, MM Paidhungat, DL Daniel, E Le Scolan, ... US Patent 11,365,233, 2022 | 1 | 2022 |
